These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401 [TBL] [Abstract][Full Text] [Related]
3. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Rodriguez-Gonzalez A; Cyrus K; Salcius M; Kim K; Crews CM; Deshaies RJ; Sakamoto KM Oncogene; 2008 Dec; 27(57):7201-11. PubMed ID: 18794799 [TBL] [Abstract][Full Text] [Related]
4. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review). Cao J; Chan WC; Chow MSS Int J Oncol; 2022 May; 60(5):. PubMed ID: 35322860 [TBL] [Abstract][Full Text] [Related]
5. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches. Hoffmann J; Sommer A J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262 [TBL] [Abstract][Full Text] [Related]
6. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways. Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399 [TBL] [Abstract][Full Text] [Related]
7. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046 [TBL] [Abstract][Full Text] [Related]
8. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342 [TBL] [Abstract][Full Text] [Related]
9. Targeting the glucocorticoid receptor in breast and prostate cancers. Kach J; Conzen SD; Szmulewitz RZ Sci Transl Med; 2015 Sep; 7(305):305ps19. PubMed ID: 26378243 [TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants. Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM Mol Cell Proteomics; 2018 Aug; 17(8):1470-1486. PubMed ID: 29632047 [TBL] [Abstract][Full Text] [Related]
11. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070 [TBL] [Abstract][Full Text] [Related]
12. Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling. El-Sayed IY; Daher A; Destouches D; Firlej V; Kostallari E; Maillé P; Huet E; Haidar-Ahmad N; Jenster G; de la Taille A; Abou Merhi R; Terry S; Vacherot F Cancer Lett; 2017 Dec; 410():100-111. PubMed ID: 28935391 [TBL] [Abstract][Full Text] [Related]
15. Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer. Mickova A; Morong M; Levková M; Kurfúrstová D; Kharaishvili G; Überall I; Student V; Student V; Drapela S; Soucek K; Bouchal J Klin Onkol; 2022; 35(6):473-481. PubMed ID: 36513514 [TBL] [Abstract][Full Text] [Related]
16. Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment. Dhimolea E; de Matos Simoes R; Kansara D; Weng X; Sharma S; Awate P; Liu Z; Gao D; Mitsiades N; Schwab JH; Chen Y; Jeselsohn R; Culhane AC; Brown M; Georgakoudi I; Mitsiades CS Cancer Res; 2021 Jan; 81(2):371-383. PubMed ID: 32859606 [TBL] [Abstract][Full Text] [Related]
17. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460 [TBL] [Abstract][Full Text] [Related]
18. Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Shafi AA; Schiewer MJ; de Leeuw R; Dylgjeri E; McCue PA; Shah N; Gomella LG; Lallas CD; Trabulsi EJ; Centenera MM; Hickey TE; Butler LM; Raj G; Tilley WD; Cukierman E; Knudsen KE Eur Urol Oncol; 2018 Sep; 1(4):325-337. PubMed ID: 30467556 [TBL] [Abstract][Full Text] [Related]
19. The biology of hormone refractory breast and prostate cancer: An NCI workshop report. Mohla S; Stearns V; Sathyamoorthy N; Rosenfeld MG; Nelson P Cancer Biol Ther; 2009 Nov; 8(21):1975-85. PubMed ID: 19783900 [TBL] [Abstract][Full Text] [Related]
20. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance. Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]